FDA Submission Update for Gabapentin by Senores Pharms
Senores Pharms has submitted a supplemental application for Gabapentin (ANDA 219319) to the FDA.
Asset / Drug
Drug and asset intelligence for Gabapentin with 22 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
The FDA has granted approval for a supplemental application for Gabapentin submitted by Zhejiang Yongtai.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.